 | DuChemBio Co., Ltd. and Life Molecular Imaging (LMI) have recently announced the signing of a Material Transfer & Clinical Supply Agreement for LMI’s next generation Tau PET Tracer PI-2620. |
PI-2620 is an investigational Tau PET agent currently in late stage clinical development by LMI with excellent characteristics and diagnostic performance for the in-vivo assessment of Tau Pathology in Alzheimer's Disease (AD) and other tauopathies by means of hybrid PET scanners.
Under the terms of the Agreement, DuChemBio, who operates the largest radiopharmacy network for a GMP-standard manufacturing of Nuclear Medicine probes for PET imaging in South Korea, has been granted a license to manufacture and supply PI-2620 clinical trial doses in South Korea.
Full Press Release
Under the terms of the Agreement, DuChemBio, who operates the largest radiopharmacy network for a GMP-standard manufacturing of Nuclear Medicine probes for PET imaging in South Korea, has been granted a license to manufacture and supply PI-2620 clinical trial doses in South Korea.
Full Press Release
